Table 1.
Demographic and clinical characteristics of patients in the comparative analysis set.
| SCHOLAR-5 before weighting (n = 143) | ZUMA-5 (n = 86) | Weighted SCHOLAR-5 (n = 85) | Weighted SMD | |
|---|---|---|---|---|
| Median age* (range) | 64 (36–89) | 62 (34–79) | 61 (36–89) | 0.036 |
| Male – no. (%) | 81 (56.6%) | 48 (55.8%) | 53 (61.9%) | 0.123 |
| Median size of largest nodal mass* (IQR) – cm | 4.2 (2.8–6.5) | 4.4 (3.3–6.4) | 4.0 (2.9–6.3) | 0.094 |
| Follicular lymphoma subtype – no. (%) | ||||
| Grade 1 | 56 (42.4) | 20 (23.3) | 30 (37.3) | 0.54 |
| Grade 2 | 61 (46.2) | 43 (50) | 42 (52.6) | |
| Grade 3a | 15 (11.4) | 23 (26.7) | 8 (10.1) | |
| Missing | 11 | 0 | 5 | |
| Median number of prior lines of therapy (range) | 2 (2–8) | 3 (2–9) | 3 (2–8) | 0.047 |
| Median time since last treatment* (IQR) – months | 6.8 (1.2–22.7) | 3.5 (1.8–9.0) | 2.3 (0.7–8.0) | 0.056 |
| Response to prior line of therapy* – no (%) | ||||
| CR | 41 (28.7) | 23.01 (26.8) | 19 (22.8) | 0.073 |
| PR | 49 (34.3) | 19.34 (22.5) | 19 (22.4) | |
| SD | 22 (15.4) | 24.15 (28.1) | 26 (31.2) | |
| PD | 31 (21.7) | 19.5 (22.7) | 20 (23.5) | |
| Refractory to prior LoT* – no. (%) | 87 (60.6) | 63 (73.3) | 65 (76.6) | 0.077 |
| POD24* – no. (%) | 51 (35.7) | 49 (57.0) | 47 (55.9) | 0.022 |
| Prior stem cell transplant* – no. (%) | 31 (21.7) | 21 (24.4) | 24 (28.0) | 0.08 |
| Median time since diagnosis (IQR) – months | 84.8 (53.0–130.5) | 59.9 (35.1–96.6) | 64.6 (41.0–115.8) | 0.10 |
| Disease stage – no. (%) | ||||
| I | 4 (6.2) | 2 (2.3) | 1 (4.6) | NE |
| II | 2 (3.1) | 9 (10.5) | 0 (1.3) | |
| III | 17 (26.2) | 35 (40.7) | 8 (27.0) | |
| IV | 42 (64.6) | 40 (46.5) | 20 (67.1) | |
| Missing | 78 | 0 | 55 | |
| Number of nodal sites – no. (%) | ||||
| 1 | 14 (15.1) | 16 (22.5) | 8 (14.1) | NE |
| 2 | 17 (18.3) | 12 (16.9) | 13 (21.5) | |
| 3 | 9 (9.7) | 7 (9.9) | 7 (10.9) | |
| >4 | 53 (57) | 36 (50.7) | 32 (53.6) | |
| Missing | 50 | 15 | 25 (29.4) | |
| FLIPI – no. (%) | ||||
| 0 | 2 (4) | 3 (3.5) | 0 (0.4) | NE |
| 1 | 4 (8) | 10 (11.6) | 2 (9.5) | |
| 2 | 11 (22) | 33 (38.4) | 4 (17.4) | |
| 3 | 19 (38) | 25 (29.1) | 7 (32.8) | |
| 4 | 10 (20) | 12 (14.0) | 6 (28.1) | |
| 5 | 4 (8) | 3 (3.5) | 3 (11.7) | |
| Missing | 93 | 0 | 62 | |
*
Variables used in propensity score weighting. The SMD for disease stage, number of nodal sites, and FLIPI were not evaluable due to missing data. See supplemental Table S5 for the SMD values before weighting. CR, complete response; FLIPI, Follicular Lymphoma International Prognostic Index; IQR, inter-quartile range; LoT, line of therapy; NE, not evaluable; PD, progressive disease; POD24, progression of disease within 24 months of starting first line chemo-immunotherapy; PR, partial response; SD, stable disease, SMD; standardized mean difference. This table was originally published in Blood, the journal of the American Society of Hematology (ASH).